Idi na sadržaj

Anemija srpastih stanica (pedijatrija)

Liječenje anemije

Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. (otvara se novi prozor)

Ambrose EE, Latham TS, Songoro P, Charles M, Lane AC, Stuber SE, Makubi AN, Ware RE, Smart LR

Izvor‎: Lancet Haematol. 2023 ;10(4):e261-71.

Indeks‎: PubMed 36870358

DOI‎: 10.1016/S2352-3026(22)00405-7

https://pubmed.ncbi.nlm.nih.gov/36870358/ (otvara se novi prozor)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (otvara se novi prozor)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Izvor‎: Acta Haematol 1995;94(3):128-34.

Indeks‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (otvara se novi prozor)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (otvara se novi prozor)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Izvor‎: Haematologica 2006;91(8):1076-83.

Indeks‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (otvara se novi prozor)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (otvara se novi prozor)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Izvor‎: J Obstet Gynaecol 2007;27(1):82-3.

Indeks‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (otvara se novi prozor)